HighTower Advisors’s Axsome Therapeutics AXSM Stock Holding History

HighTower Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$9.7M	Sell	52,557 -3,756	-7%	-$817K	0.01%	954
2026 Q2	$13.8M	Sell	56,313 -320	-0.6%	-$69.4K	0.01%	794
2026 Q1	$9.6M	Buy	56,633 +661	+1%	+$114K	0.01%	901
2025 Q4	$10.2M	Sell	55,972 -1,143	-2%	-$160K	0.01%	856
2025 Q3	$6.94M	Buy	57,115 +46,153	+421%	+$5.2M	0.01%	1005
2025 Q2	$1.14M	Sell	10,962 -2,588	-19%	-$274K	﹤0.01%	1926
2025 Q1	$1.58M	Buy	13,550 +90	+0.7%	+$10.3K	﹤0.01%	1649
2024 Q4	$1.14M	Buy	+13,460	New	+$1.24M	﹤0.01%	1873
2023 Q3	–	Sell	-2,778	Closed	-$199K	–	3579
2023 Q2	$199K	Buy	+2,778	New	+$205K	﹤0.01%	2872
2023 Q1	–	Sell	-3,328	Closed	-$256K	–	3414
2022 Q4	$256K	Buy	+3,328	New	+$199K	﹤0.01%	2589

Other funds holding AXSM

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return

Alethea Capital Management Mercer Island, Washington $197M AUM 51.86% 1-Year Est. Return

HighTower Advisors's AXSM Position: Q3 2026 in Review

HighTower Advisors reduced its Axsome Therapeutics (AXSM) stake by 6.7% in Q3 2026, selling an estimated $817K and leaving 52,557 shares worth $9.7M. The position accounts for 0.01% of the portfolio, ranked #954.

HighTower Advisors first reported a position in AXSM in Q4 2022 and has held it in 10 quarters since. The position peaked at $13.8M in Q2 2026. 348 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

HighTower Advisors held 52,557 shares of Axsome Therapeutics worth $9.7M as of Q3 2026.
HighTower Advisors sold 3,756 Axsome Therapeutics shares in Q3 2026, an estimated $817K.
Axsome Therapeutics made up 0.01% of HighTower Advisors's portfolio in Q3 2026, its #954 holding.
HighTower Advisors first reported a position in Axsome Therapeutics in Q4 2022 and has held it in 10 quarters since.
HighTower Advisors's Axsome Therapeutics position peaked at $13.8M in Q2 2026.
348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.